GNCA Genocea Biosciences Inc.

+0.01  (+1%)
Previous Close 0.69
Open 0.7
Price To Book 11.61
Market Cap 78315752
Shares 112,393,445
Volume 175,280
Short Ratio
Av. Daily Volume 521,754

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Announced September 25, 2017 that development will be ceased.
Genital herpes
Topline data did not meet endpoints - September 2015
Universal vaccine candidate against pneumococcus
Phase 1/2 initial immunogenicity data due mid-2019.
GEN-009 vaccine
Various cancers

Latest News

  1. Genocea to Present at 18th Annual Needham Healthcare Conference
  2. Genocea Presents Data at AACR 2019 Supporting Utility of ATLAS™ Platform in Predicting Melanoma Patient Response to Immune Checkpoint Inhibitors
  3. Top Ranked Momentum Stocks to Buy for March 20th
  4. Edited Transcript of GNCA earnings conference call or presentation 28-Feb-19 2:00pm GMT
  5. Will Genocea Biosciences Continue to Surge Higher?
  6. Genocea to Present at the Cowen & Company 39th Annual Health Care Conference
  7. Genocea Reports Fourth Quarter 2018 Results and Announces Hiring of New Chief Financial Officer
  8. Genocea to Host Quarterly Corporate Update Conference Call & Webcast on February 28 at 9:00 am ET
  9. Genocea Announces Private Placement Financing of Up to $39 Million
  10. How Does Investing In Genocea Biosciences, Inc. (NASDAQ:GNCA) Impact The Volatility Of Your Portfolio?
  11. These 4 Healthcare Stocks Are Kicking Off The New Year With A Bang
  12. Genocea Doses First Patients and Completes Enrollment in Part A of Phase 1/2a Clinical Trial for Neoantigen Vaccine Candidate GEN-009
  13. Read This Before Selling Genocea Biosciences, Inc. (NASDAQ:GNCA) Shares
  14. Genocea Appoints Girish Aakalu, Ph.D., Chief Business Officer
  15. Detailed Research: Economic Perspectives on Genocea Biosciences, Big Lots, SemGroup, Conn's, Mimecast, and Neos Therapeutics — What Drives Growth in Today's Competitive Landscape
  16. Genocea To Host a Key Opinion Leader Event November 26th on Latest Advances in Personalized Cancer Immunotherapies
  17. Edited Transcript of GNCA earnings conference call or presentation 1-Nov-18 1:00pm GMT
  18. Genocea Unveils Possible Mechanism for Tumor Resistance to Immunotherapy at Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
  19. Genocea Biosciences: 3Q Earnings Snapshot